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63 Abstract
64 Quantitative real-time PCR (qPCR) is increasingly used to detect Pneumocystis jirovecii for the 
65 diagnosis of Pneumocystis pneumonia (PCP), but there are differences in the nucleic acids 
66 targeted, DNA only versus whole nucleic acid (WNA), and also the target genes for 
67 amplification. Through the Fungal qPCR Initiative, a working group of the International Society 
68 for Human and Animal Mycology, a multicentre and monocentre evaluation of PCP qPCR 
69 assays was performed. For the multicentre study, 16 reference laboratories from eight 
70 different countries, performing 20 assays analysed a panel consisting of two negative and 
71 three PCP positive samples. Aliquots were prepared by pooling residual material from 20 
72 negative or positive- P. jirovecii bronchoalveolar lavage fluids (BALFs). The positive pool was 
73 diluted to obtain three concentrations (pure 1:1; 1:100; and 1:1000 to mimic high, medium, 
74 and low fungal loads respectively). The monocentre study compared five in-house and five 
75 commercial qPCR assays testing 19 individual BALFs on the same amplification platform. 
76 Across both evaluations and for all fungal loads, targeting WNA and the mitochondrial small 
77 sub-unit (mtSSU) provided the earliest Cq values, compared to only targeting DNA and the 
78 mitochondrial large subunit, the major surface glycoprotein or the beta-tubulin genes. Thus, 
79 Reverse Transcriptase-qPCR targeting the mtSSU gene could serve as a basis for standardizing 
80 the P. jirovecii load, which is essential if qPCR is to be incorporated into clinical care pathways 
81 as the reference method, accepting that additional parameters such as amplification 
82 platforms still need evaluation. 
83
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84 INTRODUCTION
85 Pneumocystis jirovecii is an atypical ascomycetous fungus responsible for Pneumocystis 
86 pneumonia (PCP), a severe respiratory infection in immunocompromised patients such as 
87 those with HIV/AIDS, organ transplant recipients, patients affected by haematological 
88 malignancies and patients under immunosuppressive therapies.1 Healthy humans are a 
89 reservoir of P. jirovecii resulting in likely continuous inter-individual circulation responsible for 
90 further transmission to immunocompromised hosts.2 Once acquired by a susceptible host, the 
91 fungal load increases from undetectable to a high fungal burden leading to full blown 
92 pneumonia.2,3 However, PCP is more severe and mortality rates are significantly higher in non-
93 HIV patients than in HIV-infected/AIDS people, despite a lower fungal load during infection.4 
94 Therefore, diagnosis of PCP remains a challenge because of the importance of quantification 
95 and detection of low fungal loads.
96 Conventional diagnosis of PCP relies on visualization of asci and trophic forms of P. 
97 jirovecii by conventional staining (Giemsa, methenamine silver, Toluidine Blue O) or by 
98 immunofluorescence using anti-trophic form and/or anti-asci antibodies.5 These methods 
99 depend on staff experience and results can be falsely negative in the case of low fungal load, 
100 particularly in non-HIV patients.4 Recently, the detection in serum of β-1,3-D-glucan (BDG), an 
101 antigen present in most fungi including P. jirovecii, has been shown to be a valuable biomarker 
102 for PCP.6 However, high BDG titres could be due to the presence of another invasive fungal 
103 infection, and the test is prone to numerous causes of false positivity.7-9 Moreover, serum BDG 
104 levels have been shown to be low in non-HIV patients with PCP.10 Therefore, nucleic acid 
105 detection in respiratory specimens appears more reliable for confirming or excluding the 
106 diagnosis of PCP. 
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107 Various molecular assays allowing detection of P. jirovecii DNA have been developed in 
108 the past 30 years. Real-time quantitative PCR assays (qPCR) are the most suitable options for 
109 diagnostic laboratories, providing rapid and quantitative results indispensable for diagnosing 
110 PCP, and a significant reduction in the risk of false positive results by preventing exposure to 
111 prior amplicon contamination and excluding post-amplification processing.5,11-13 Several 
112 meta-analyses reported the excellent performance of qPCR to aid diagnosis of PCP. However, 
113 detection of P. jirovecii DNA in respiratory samples has been observed in asymptomatic 
114 immunocompromised patients leading to the concept of carriage/colonization and the 
115 requirement for strategies discriminating between this and active infection.3 Only qPCR has 
116 the potential to be used to differentiate active infection from colonisation, provided fungal 
117 burden thresholds for infection in each patient group can be determined. Currently, definite, 
118 consensual thresholds for PCP PCR in non-HIV patients have not been established and 
119 universally used in different diagnostic laboratories,5 partially due to the wide diversity of the 
120 qPCR assays described and used in diagnostic centres. Some studies have compared the 
121 performance of different P. jirovecii qPCR assays, but these studies mainly reported intra-
122 laboratory comparison of two to four qPCR assays, including commercial kits and various in 
123 house assays.14-22
124 The Pneumocystis working party of the Fungal PCR Initiative, a working group of the 
125 International Society for Human and Animal Mycology, initiated two studies. The first one was 
126 aimed at evaluating the variability of the performance of 20 in-house and commercial assays 
127 currently used in reference laboratories with the final goal of providing a consensus method 
128 for P. jirovecii qPCR, comparable to the process used for Aspergillus qPCR.23 For this purpose, 
129 a panel of five samples with various P. jirovecii whole nucleic acid concentrations were tested 
130 by 16 reference laboratories. The second study was performed in parallel in one centre testing 
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131 10 different qPCR assays available at that time in centre E using the same clinical samples and 
132 PCR amplification instrument.
133
134 MATERIALS AND METHODS
135 Multicentre inter-laboratory evaluation of P. jirovecii qPCR assays
136 Panel specimen production
137 The broncho-alveolar lavage fluids (BALFs) were obtained through routine diagnostic practice 
138 for the patients in Centre E.20 After performing routine investigations, surplus clinical material 
139 was retained for quality and service evaluation purposes, as permitted by the French Health 
140 Public Law (CSP Art L1121-1.1). All further preparation and subsequent dispatching of aliquots 
141 were performed in a biosafety cabinet. 
142 Whole nucleic acids (WNA) were extracted from 900 µL of concentrated BALF pellet (5 
143 min at 10000 g) with addition of 10 µL/sample of 1:5 diluted internal control (DNA Virus 
144 Culture, DICD-CY-L100, Diagenode, Seraing, Belgium) using a Qiasymphony (Qiagen, Hilden, 
145 Germany) with the Virus-Pathogen Kit (Qiagen) following the manufacturer’s instructions. 
146 WNA was eluted in 85 μL, of which at least 30 μL was used for the routine diagnosis. Eluates 
147 were tested for the presence of P. jirovecii WNA using mitochondrial large sub-unit (mtLSU) 
148 qPCR assay to detect positive specimens. Mitochondrial small sub-unit (mtSSU) reverse 
149 transcriptase (RT)-qPCR (as the most known sensitive method in our centre) was used to select 
150 negative specimens. For the qPCR assays, the protocols published by Valero et al. were 
151 followed.20 All the experiments were performed on a Light Cycler 480 thermocycler (LC480-II; 
152 Roche Diagnostics, Mannheim, Germany) with Cq determined with the second derivative 
153 method. For the RT-qPCR assay targeting also mtLSU and mtSSU RT-qPCR, the protocol was 
154 different to include the reverse transcription step: 1× Invitrogen RT-PCR buffer mix 
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155 (Superscript III One step RT-PCR), 0.3 µM of each primer, 0.1 µM of probe, 1 µM of MgSO4 (to 
156 reach a Mg concentration of 4 mM), and 1 µM of Superscript III Platinum enzyme, in a total of 
157 25 µL with 5 µL of WNA extract. The amplification consisted of one step of RT-PCR at 50°c for 
158 15 minutes, followed by qPCR with one activation step at 95°C for 2 minutes and 50 cycles of 
159 denaturation at 95°C for 15 seconds and annealing at 60° for 30 seconds. As guided by the 
160 internal control values, only the BALFs with no evidence of PCR inhibition were used for 
161 further analyses. The amplification results were expressed as quantification cycle (Cq) values.
162 To provide negative material, WNA extracts from 50 P. jirovecii qPCR negative BALFs 
163 were pooled. Fifteen microliters of this negative pooled extract were used for the two 
164 negative panel specimens. This negative pooled extract was also used to dilute the positive 
165 samples, instead of using water, to better mimic the human BALF and maintaining a typical 
166 human WNA concentration. As an approximation of the human DNA content, the human 
167 albumin gene was quantified by qPCR, as previously reported.24 The result corresponds to 1.6 
168 to 1.7x107 human cells. We determined that the human to P. jirovecii ratio in the 1:1 specimen 
169 was 1000:1, (1000-fold more human DNA than P. jirovecii DNA).
170 For the positive panel specimens, WNA extracts from residual clinical material of three 
171 P. jirovecii PCR-positive patients were pooled. This positive pool was diluted in the negative 
172 pooled extract to obtain different fungal dilutions (pure 1:1; and 1:100; and 1:1000 dilutions), 
173 thereafter deemed high, medium, and low fungal loads. Thus, 40 15-µl positive aliquots were 
174 obtained for the multicentre study. The aliquots were stored at -20°C before distribution. To 
175 mimic unexpected thawing during transportation, aliquots were thawed and tested 
176 immediately after thawing and after 15 days at room temperature.
177 According to the French Health Public Law (CSP Art L1121-1.1), such protocol does not 
178 require approval of an ethics committee and is exempt from specific informed consent 
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179 application. However, the patients were informed and gave consent for the possibility of using 
180 leftover material for additional laboratory studies before the broncho-alveolar lavage 
181 procedure.
182 Panel distribution to participating laboratories
183 The participating laboratories were 16 reference laboratories anonymised for blind 
184 comparison (Centre A to P). The panel consisted of five 15-µl WNA aliquots comprising three 
185 P. jirovecii positives and two negatives sent on dry ice. The laboratories were asked to use 
186 their own qPCR assay running currently in their lab (listed in Table 1). The primer and probes 
187 used in the in-house assays are listed in Supplemental Table 1. In short, 5 μL of each extract 
188 were asked to be tested in duplicate using the qPCR process routinely available in their 
189 laboratory. The results were collected using a dedicated form that included requests for the 
190 qualitative result (positive/negative), the Cq value for each replicate related to each aliquot 
191 and specific information regarding the methods and workflows applied (Supplemental Table 
192 2). 
193 Quantification cycles (Cq) normalization
194 For comparability between assays, Cq values were normalized as per the volume of nucleic 
195 acid tested for each qPCR assay, adjusted to a standard volume of 5 µL (1 Cq subtracted if 10 
196 µL of extract were recommended). In addition, one commercial assay (Sacace Biotechnologies, 
197 Como, Italy) recommended recording fluorescence intensity during qPCR only after 5 first 
198 cycles, which artificially decreased the Cq value obtained at the end of the run. So, for 
199 comparability, 5 cycles were added to the value obtained with this kit.
200
201 Monocentre intra-laboratory evaluation of different qPCR assays using clinical BALFs 
202 Sample preparation
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203 For this monocentre comparison, we selected 10 P. jirovecii-negative and 9 P. jirovecii –
204 positive BALFs. The 50 µl of the BALF extracts left after routine procedure were combined with 
205 70 µl of negative extract (see above), to provide sufficient material for the comparison of the 
206 kits. Verification was performed using the mtSSU in house RT-qPCR assay which generated 
207 initial Cq values ranging from 17 to 30 cycles for the 9 qPCR-positive BALF extracts . All aliquots 
208 were stored at -20°C until use. 
209 To calculate the qPCR efficiency of each assay, calibration curves were generated using 
210 the highest positive BALF extract (BALF9: initial Cq=17 with the mtSSU in-house RT-qPCR 
211 assay). After thawing of an aliquot, a serial dilution of the extract (6 times at 1:5 ratio in 
212 negative pooled extract) was tested for each PCR assay. 
213 qPCR assays tested
214 Centre E compared 10 different assays based on the in-house assays available locally 
215 and the commercial assays available in his country with the same person and the same qPCR 
216 instrument as above. For Centre E in-house assays, the same protocols as above were used. 
217 Commercial qPCR assays were performed following the manufacturer’s instructions. The 
218 major surface glycoprotein (MSG) in-house DNA assay was performed following instruction of 
219 the detailed process described in Larsen et al.25
220 Technical information on the 10 assays, consisting of 5 in-house assays and 5 
221 commercial kits, are listed in Table 1 and the primers and probes used are available in 
222 Supplemental Table 1. They consisted in 1 commercial and 2 in-house RT-qPCR assays, and 4 
223 commercial and 3 in-house qPCR assays. The targets were mtLSU (7 assays); mtSSU (2 assays); 
224 and one nucleic gene: Major Surface Glycoprotein (MSG, 1 assays) (Table 1). 
225
226 Statistical analysis
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227 For the multicentre study, 20 datasets of the five samples tested by each assay in duplicate 
228 were produced. Therefore, the total number of data values included was 200. Each replicate 
229 was analysed as an independent result. Negative results were allocated a value of 45 cycles. 
230 Descriptive statistics were performed calculating summary indexes of Cq at all target loads, 
231 pure (1:1) and 1:100, 1:1000 dilutions.
232 An ANOVA model was used to evaluate the effect of a two main covariables: DNA vs. 
233 WNA, and target gene. The effects of these categorical covariates were quantified by adding 
234 each of them consecutively to a basic ANOVA model. An ANOVA model was applied as (1) the 
235 real/absolute amount of the fungal burdens were unknown and the ANOVA approach 
236 overcame this by simply assuming that the panel samples 2, 3, and 5 are different; (2) the 
237 linearity of the relationship Cq/logRLM was not guaranteed; (3) the difference between the 
238 effects exerted by two levels of an added covariate would unlikely be constant across all Cq 
239 values. The ANOVA analysis was implemented as a mixed effects regression model, where Cq 
240 was the dependent variable, the molecular target level was used as categorical regressor, and 
241 the covariate under evaluation was added as an additional factor. The interaction between 
242 the covariate and the relative genomic load was also included in the model. Anonymization 
243 was performed prior to all analysis and identifiers were used to build the categorical grouping. 
244 The identifier indicated the mixed model categorical grouping variable. As a post-estimation 
245 step, the contrasts (predicted mean effects) were calculated for each pair of factor levels, 
246 adjusting for each relative genomic load level. They measured the difference between the 
247 effects exerted by each member of the factor pair on the signal intensity.
248 For the monocentre study, no specific statistical analysis was applied.
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249 RESULTS
250 Multicentre inter-laboratory evaluation of P. jirovecii qPCR assays
251 The effects of shipping on the stability of DNA and WNA in the panel was investigated in Centre 
252 E after panel storage for 15 days at room temperature, after a freezing-thawing cycle. Using 
253 mtLSU DNA and mtSSU WNA detection, the coefficient of variation was 2.5%, 1% and 1% for 
254 mtLSU DNA and 2.2%, 1.4%, 1.9% for mtSSU WNA in samples, respectively (Supplemental 
255 Figure 1). All samples were found to be stable indicating that the distribution process did not 
256 introduce bias in the results, even when shipping samples from Europe to Australia.
257 There were 16 participating laboratories across eight countries including seven 
258 European countries and Australia. Two centres tested more than one qPCR assays (two in 
259 Centre K, and four in Centre E). Thus, 20 qPCR assays were evaluated based on 15 commercial 
260 and in-house assays available in literature. In this study, assay#2 was tested by 5 centres (B, 
261 C, E, J, O) and #12 by 2 centres (K, P) (Table1). Sixteen qPCR amplifying DNA only and 4 RT-
262 qPCR assays amplifying WNA were tested. Six of 15 assays were commercial, for which two 
263 out of six were tested directly by the manufacturers (Table 1, Supplemental Table 1). The 
264 targets were mtLSU (11 assays); mtSSU (2 assays); and two nucleic gene: Major Surface 
265 Glycoprotein (MSG, one assay) and beta-tubulin (TUB, one assay).
266 No false-positive amplification was observed (80/80 negative tests) for the two 
267 negative aliquots, which set the specificity at 100% (95% CI: 95.4-100). For each positive 
268 aliquot tested 40 times (20 assays in duplicates), 40/40 tests were positive at 1:1 (both 
269 replicates of the 20 assays) (sensitivity =100%, 95% CI: 91.2-100); 38/40 tests were positive at 
270 1:100 (sensitivity=95%, 95% CI: 83.5-98.6), with one replicate negative for 2 assays (#4 and 
271 #6). At 1:1000, 33/40 tests were positive (sensitivity=82.5%, 95% CI: 68.1-91.3), with both 
272 replicates negative for one assay (#6) and only one replicate negative for three assays across 
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273 five centres (#2 centre B, C, O, #3 #16) (Table 2, Supplemental Figure 2 and Supplemental 
274 Table 3 and 4)
275 The maximum variation in the Cq value (excluding negative values) between assays 
276 was 12.4 cycles (approximately 10,000-fold variation), 9.2 and 9.4 cycles (approximately 1000-
277 fold variation) for the 1:1, 1:100 and 1:1000 panel specimens, respectively (Supplemental 
278 Figure 2). Of note, mtLSU assays using the same primers and probes,26 but with different 
279 reagents and/or protocol, gave a median difference of 3 cycles (i.e. 10-fold variation) 
280 (Supplemental Table 5). 
281 Two major variables impacted significantly on the results, in addition to minor 
282 influences associated with variation in reagents and protocols: (i) the type of qPCR, RT-qPCR 
283 vs qPCR, and (ii) the gene targeted for amplification (Figure 1). The RT-qPCR assays based on 
284 the detection of WNA (detecting both RNA and DNA) were significantly superior to qPCR 
285 assays detecting DNA only at all loads (p<0.001, Supplemental Table 6 and Supplemental 
286 Figure 3). The Cq values were also significantly associated to the target gene at all loads with 
287 the lowest Cq values associated with mtSSU, successively followed by mtLSU, MSG, and then 
288 TUB (Figure 1, Supplemental Table 7). There was a consistent and significant correlation 
289 associated with Cq values generated by mtSSU assays amplifying WNA through to TUB assays 
290 amplifying DNA only (ANOVA Kruskal-Wallis p<0.05) across all nucleic acid loads. The Cq values 
291 obtained with the 3 panel specimens and the 20 PCR assays are represented Figure 2A. Indeed, 
292 a mean 7 Cqs difference (200-fold variation) was observed between the TUB assay and the 
293 assays targeting multicopy genes.
294
295 Monocentre intra-laboratory evaluation of 10 P. jirovecii qPCR assays
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296 The specificity of the 10 assays was high; nine gave a specificity of 100% (upon duplicate 
297 testing of the 10 negative BALFs) and only one assay (assay#12) provided one false-positive 
298 result (one of the duplicates) giving a specificity of 95%.
299 The sensitivity of the assays for the detection of P. jirovecii in 9 positive BALFs varied 
300 between 88.8% (n=5 assays) and 100% (n=2 assays) with 4 assays having a sensitivity of 94.4% 
301 (Supplemental Table 8 and Figure 2B). The lowest Cq values were observed with the mtSSU 
302 assays amplifying WNA and the highest with the MSG assays amplifying DNA across all positive 
303 BALFs (Figure 2B). Thus, when excluding the negative values (Cq=45), the median of the 
304 maximum variation of the Cq value between the 10 assays was 8.23 (approximately 500-fold 
305 variation) for a given BALF. Even when considering the 5 commercial assays targeting mtLSU 
306 as the target, a median of variation as high as 3.1 (about 10-fold variation) was observed 
307 (Supplemental Table 8 and Figure 2B).
308 By serially diluting BALF#9 WNA extract five times at 1:5 dilutions, the qPCR efficiency 
309 for each assay was calculated. The amplification efficiency calculated from the Cq values were 
310 all between 94 and 113% (Supplemental Table 8, Supplemental Figure 4). This showed that 
311 this factor can be discarded as a possible explanation for the differences observed above.
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312 DISCUSSION
313 The present study underlines the necessity of comparing different assays for the 
314 quantification of the P. jirovecii loads. Indeed, large variation was evidenced among all the 
315 assays compared. Based on data of 9 commercial kits and 10 in house assays tested in the 
316 multicentre and monocentre studies (Table 1), this variation ranged from 500-fold (5 qPCR 
317 cycles) to 10,000-fold (12 qPCR cycles) between the assays. 
318 This resulted mainly from the target gene (mitochondrial multicopy genes vs. single copy 
319 nuclear gene) and the qPCR method/template (qPCR/DNA versus RT-qPCR/WNA). Thus, our 
320 studies showed that using mtSSU as the target gene and WNA as the starting material yielded 
321 the best sensitivity. Predictably, assays targeting multi copy genes provided the best analytical 
322 sensitivity, as already shown.16,19,20 This was observed in our study for the single copy gene 
323 (beta-tubulin) compared to the mtSSU gene (about 200-fold variation). However, among the 
324 repeated genes, MSG assay gave higher/later Cq values than mtLSU or mtSSU, suggesting a 
325 lower number of repeats for the MSG gene. The MSG gene sequence is reported to be highly 
326 variable,27 which can impacts both the analytical sensitivity/limit of detection (risk of false 
327 negative) and qPCR efficiency (risk of variable amplification yield). 
328 Among the mitochondrial multicopy assays, the mtSSU assay was two times more 
329 sensitive on average than the mtLSU assay, possibly as a result of the higher number of repeats 
330 of mtSSU compared to mtLSU in the mitochondrial genome.20 Interestingly, the number of 
331 copies of some mitochondrial genes (mtLSU, NAD1 and CYTB) have been shown to vary 
332 according to the fungal load (high vs. medium and low fungal loads).20 In contrast, mtSSU 
333 seems to remain stable between these conditions suggesting that a more reliable 
334 quantification could be achieved with mtSSU rather than with other mitochondrial targets. 
335 Indeed, the quantification of unique/single copy gene (nuclear) will better reflect the quantity 
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336 of microorganism, but the lack of sensitivity of such a target gene hampers its use for clinical 
337 diagnosis.
338 Interestingly, even when a given gene is targeted or the same primer/probes utilized, 
339 differences can occur. Using the same mtLSU primers and probes and qPCR,26 the 
340 quantification obtained from five centres showed here a median 3-fold variation in the Cq (10-
341 fold difference in concentration). In addition, we showed that five commercial mtLSU kits also 
342 gave a 3-fold variation in the Cq. Overall, these differences can come from the different primer 
343 concentration/amplification kits/enzyme or thermocyclers used. Indeed, technical 
344 parameters can affect qPCR efficiency, such as the type of polymerase used, the concentration 
345 of oligonucleotides or the method of Cq determination, suggesting that harmonization of the 
346 methods requires more than standardization of the target gene or the primer sequences. 
347 Although differences were already known among different DNA extraction methods or 
348 qPCR assays,14-22 the superiority of WNA over DNA extraction has never been reported for P. 
349 jirovecii, due to lack of prior of investigation. WNA RT-qPCR amplification kits were initially 
350 developed for virology to allow cDNA and genomic DNA amplification in the same run to 
351 detect both RNA or DNA viruses.28,29 Currently, most of the automated extractors allow WNA 
352 extraction to test for the presence of both RNA or DNA viruses, and DNA from other 
353 pathogenic organisms in the same sample extract as part of a syndromic investigation.30 Such 
354 strategy has already been tested with success for detecting P. jirovecii DNA in samples 
355 dedicated for influenza diagnosis.24 Thus, since WNA extraction does not interfere with the 
356 detection of P. jirovecii and even provides the best sensitivity in the present study, this 
357 extraction method could be recommended.
358 The rationale for supporting the use of the quantitative assays with the highest 
359 sensitivity might be contentious as low fungal loads are often considered to represent 
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360 “carriage/colonization” and therefore of limited clinical significance. However, if the negative 
361 predictive value of the assay to exclude PCP is taken into consideration, it seems preferable 
362 to rely on optimal sensitivity to exclude PCP, rather than managing false negative results. 
363 Indeed, low P. jirovecii burden can be associated with severe disease in HIV-negative 
364 patients.31 Second, prophylaxis could be considered for immunocompromised patients with a 
365 low fungal load to avoid subsequent development of full-blown PCP.32 At least, knowing that 
366 P. jirovecii is detectable can tilt the balance between continuing co-trimoxazole or stopping 
367 the drug because of the fear of side effects. Third, patients with low fungal loads in an hospital 
368 environment can be part of the onward transmission chain in clinical outbreaks.3,31 
369 There are limitations to this study. To set up a quality control with P. jirovecii, one must 
370 consider the difficulty of obtaining cultured material. Realistically, only surplus human 
371 samples can be used and these are limited in both number and sample volume. Hence the 
372 choice of pooling human samples and the limited number panel size used for comparison. In 
373 pooling samples, it is acknowledged that potential biases are introduced. Ideally, it would have 
374 been preferable to select a specific patient, to have an idea of the sequence of the P. jirovecii 
375 main target genes and to propose individual panel specimens based on well-defined 
376 organisms. Unfortunately, this is impossible due to limited sample volume. Since the BALF 
377 material is usually limited after performing thorough routine diagnostics testing, such previous 
378 analysis, providing 20 aliquots of several individual BALF extracts is practically impossible. The 
379 pooling of BALF extracts also assesses the amplification process in the presence of the genetic 
380 variability. In addition, it has been shown that PCP episodes are due to multiple genotypes in 
381 more that 70% of the cases,33-36 with known sequence variation in targets genes.33
382 Indeed, false negative results can result from the choice of primers in variable regions of the 
383 fungus.37 This is therefore the responsibility of each centre to investigate this when facing a 
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384 high clinical suspicion of PCP and our quality control did not address this possibility. For 
385 example, MGB probes who are very sensitive to polymorphism/mismatch should not be used 
386 to avoid the risk of false negative result.37
387 The absolute quantity of Pneumocystis DNA added in the initial pooled of samples was not 
388 known. Nevertheless, the main purpose of our study was to compare different assays and not 
389 to determine the absolute analytic capacity of each assay. Another possible bias in pooling 
390 human samples is to dilute PCR inhibitors present in one of the samples for elaborating the 
391 panel. Using an internal control is of outmost importance to analyse qPCR results in a 
392 diagnostic lab and is strongly advocated38,39 and improves the quality of the results, especially 
393 to have a strong validation for negative results.40 Thus, some PCR assays not controlling for 
394 the presence of PCR inhibitors can be falsely over-evaluated in the present study. With limited 
395 availability of Pneumocystis culture the current methodology based on surplus human 
396 samples is the only one possible to perform such evaluations, despite all the inherent potential 
397 bias. However, we do not think the possible limitations listed above had a major impact on 
398 our comparative studies.
399 The limited quantity of BALF extract available restricted the number of evaluations 
400 possible. Thus, some assays were tested only once in a single centre (DNA MSG, DNA TUB, 
401 WNA mtSSU, DNA mtSSU) making any evaluation on the reproducibility for these specific 
402 assays impossible. Additionally, only the analytical sensitivity of the amplification was tested, 
403 not the nucleic acids extraction step, which has a major impact for the global performance of 
404 all the amplification procedure.41 We also did not have the opportunity to evaluate the impact 
405 of qPCR platform (thermocycler and Cq determination), because too many parameters varied 
406 among the different centres. There are future plans to implement specific studies on these 
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407 topics to show the impact of extraction, qPCR platform and the use of an internal control on 
408 the performance of P. jirovecii qPCR.
409
410 CONCLUSION
411 Our present studies confirm the large variation between of qPCR assays to quantify P. jirovecii 
412 nucleic acids. This large variation, up to 12 cycles (10,000-fold variation) for a given sample, 
413 makes reaching a consensus threshold value to distinguish between low and high fungal loads 
414 in respiratory samples difficult, but highlights optimal assays in regards to sensitivity. The most 
415 sensitive association was shown to be RT-qPCR (amplifying combined RNA and DNA) targeting 
416 the mtSSU gene and the less sensitive the qPCR assays (DNA only) targeting Major Surface 
417 Glycoprotein and the unique beta-tubulin gene targets using. Interpretative thresholds might 
418 be defined in the future, provided centres agree to use the most sensitive method. Other 
419 factors not directly related to the PCR process that influence the result, such as the protocol 
420 for processing the fluid must, however, be performed. Future harmonization of the results 
421 should also take into account the procedure for obtaining broncho-alveolar lavage or other 
422 respiratory specimens. 
423
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435 Table 1. Characteristics of the assays used in these studies. Five centres (B, C, E, J, O, E*) used the same in-house mtLSU assay as described 
436 previously26 and two centres (L, E*) used the same commercial assay.
Assay 
ID
Centre ID 
(Multicentre 
study)
Target PCR Type Multicentre 
study
Monocentre 
study
In House 
assays
Commercial 
assays
Name of the kit or publication (PMID) Manufacturer
1 A mtLSU qPCR X X 26739439
2 B, C, E, J, O, E* mtLSU qPCR X X X 20946413
3 D mtLSU qPCR X X Unpublished1
5 E, E* mtSSU qPCR X X X 27672381
6 H TUB qPCR X X 15767014
7 I mtLSU qPCR X X Unpublished2
8 M mtLSU RT-qPCR X X Unpublished3
9 E, E* mtLSU RT-qPCR X X X 20946413
10 E, E* mtSSU RT-qPCR X X X 27672381
11 E* MSG qPCR X X 11825961
4 F mtLSU qPCR X X Pneumocystis jirovecii REAL TIME PCR, PG1905 Ridagene
12 K, P, E* mtLSU qPCR X X X PneumoGenius (PN-600) Pathonostics
13 N mtLSU qPCR X X PneumID (Ref OLM2008) OLM
14 K mtLSU qPCR X X Pneumocystis jirovecii (carinii) Real-TM, P2-50FRT Sacace Biotechnologies
15 L, E* mtLSU RT-qPCR X X X FTD Pneumocystis jirovecii Fast Track Diagnostics
16 G MSG qPCR X X LightMix Modular Pneumocystis jiroveci Roche
17 E* mtLSU qPCR X X RealStar® Pneumocystis jirovecii PCR Kit 1.0 Altona
18 E* mtLSU qPCR X X RealCycler PJIR Kit Progenie molecular
19 E* mtLSU qPCR  X  X Pneumocystis jirovecii qPCR (BE-A994) Bioevolution
437 E*: evaluation in Centre E in the monocentre study ; qPCR: quantitative PCR; RT-PCR: reverse-transcribed quantitative PCR. Mitochondrial Large Sub-Unit 
438 (mtLSU); mitochondrial Small Sub-Unit (mtSSU); Major Surface Glycoprotein (MSG); beta-tubulin (TUB).
439
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440 Table 2. Descriptive statistics.
Fungal load N mean SD min p25 p50 p75 max
Negative 80 45 0 45 45 45 45 45
Cq at 1:1000 40 37.704 3.985 30.400 35.325 37.090 38.615 45
Cq at 1:100 40 33.956 3.423 28.940 31.615 33.545 35.100 45
Cq at 1:1 40 26.831 2.682 22.900 24.890 26.760 27.700 35.200
441 PCR summary results, as Cq means, standard deviations, 25th - 50th -75th percentiles. The number of the DNA assays is indicated (N). Relative 
442 genomic loads are indicated as 0, 1:1000, 1:100, and 1:1. 
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443 Legends to Figures
444 Figure 1: Cq variation for each assay regarding the target gene and the type of material 
445 amplified (DNA or WNA) in all the three positive panel samples at dilutions 1:1 (A), 1:100 
446 (B), and 1:1000 (C). It shows the gain in the ability to detect the target (lower Cq) in WNA 
447 assays compared to DNA and with a gradient from mtSSU to TUB genes 
448 (mtSSU>mtLSU>MSG>TUB)
449
450 Figure 2: Cq variation in all assays tested in the multicentre (A) and in the monocentre study 
451 (B). For the multicentre study, the panel specimen 1:1 (open circle) 1:100 (open square), 
452 1:1000 (black circle) were tested in duplicates among 20 PCR assays tested (assay#2 was 
453 tested by 5 centres and assay#12 by 2 centres, see Table 1). For the monocentre study, 9 
454 human broncho-alveolar lavage fluids (BALF1 to BALF9 highlighted by different symbols) were 
455 tested in duplicates with 10 in house and commercial assays. It shows that assay#10 (mtSSU 
456 and RT-qPCR) gives the best Cq values. 
457
458
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459 Supplemental material
460
461 Supplemental Figure 1: Stability of nucleic acids (mtLSU DNA and mtSSU WNA) obtained in 
462 all 3 samples (1:1, 1:100, 1:1000) immediately thawing (D0) and after 3 (D3), 8 (D8) or 15 
463 (D15) days at room temperature after one thawing/freezing cycle (A) or pooled (B).
464
465 Supplemental Figure 2: Cq variation of the three positive panel specimens at dilutions 1:1, 
466 1:100, and 1:1000 upon evaluation by the 20 qPCR assays in the multicentre study. Each dot 
467 represents each Cq value of the duplicate performed in each centre (40 Cq values by 
468 specimen). Negative amplifications have been plotted with a Cq at 45.
469
470 Supplemental Figure 3: Cq variation in assays amplifying mtLSU DNA or mtLSU Whole 
471 Nucleic Acids (WNA) for each panel sample. It shows the gain in the ability to detect the target 
472 (lower Cq) in WNA assays compared to DNA.
473
474 Supplemental Figure 4: Calibration curves for each of the 11 assays tested using 1:5 dilutions 
475 of BAL1 harbouring the highest fungal load in the monocentre study.
476
477
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Cq variation for each assay regarding the target gene and the type of material amplified (DNA or WNA) in all 
the three positive panel samples at dilutions 1:1 (A), 1:100  (B), and 1:1000 (C). It shows the gain in the 
ability to detect the target (lower Cq) in WNA assays compared to DNA and with a gradient from mtSSU to 
TUB genes (mtSSU>mtLSU>MSG>TUB) 
95x272mm (300 x 300 DPI) 
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Supplementary Figure 1: Stability of nucleic acids (mtLSU DNA and mtSSU WNA) obtained in all 3 samples (1:1, 1:100, 1:1000) immediately 
thawing (D0) and after 3 (D3), 8 (D8) or 15 (D15) days at room temperature after one thawing/freezing cycle (A) or pooled (B). 
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Supplemental Figure  2: Cq variation of the three positive panel specimens at dilutions 1:1, 1:100, and 1:1000 upon evaluation by the 20 
qPCR assays in the multicentric study. Each dot represents each Cq value of the duplicate performed in each centre (40 Cq values by 
specimen). Negative amplifications have been plotted with a Cq at 45. 
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Supplemental Figure 3: Cq variation in assays amplifying mtLSU DNA or mtLSU Whole Nucleic Acids (WNA) for each panel sample. It shows 
the gain in the ability to detect the target (lower Cq) in WNA assays compared to DNA. 
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Supplemental Figure 4: Calibration curves for each of the 11 assays tested using 1:5 dilutions of BAL1 harbouring the highest fungal load in 
the monocentric study. 
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Cq variation in all assays tested in the multicentre (A) and in the monocentre study (B). For the multicentre 
study, the panel specimen 1:1 (open circle) 1:100 (open square), 1:1000 (black circle) were tested in 
duplicates among 20 PCR assays tested (assay#2 was tested by 5 centres and assay#12 by 2 centres, see 
Table 1). For the monocentre study, 9 human broncho-alveolar lavage fluids (BALF1 to BALF9 highlighted by 
different symbols) were tested in duplicates with 10 in house and commercial assays. It shows that assay 
#10 (mtSSU and RT-qPCR) gives the best Cq values. 
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Supplemental Tables 
 
 
 
Supplemental Table 1: Primers of the in-house qPCR assays 
 
 
 
  
Assay ID Forward primers 5'-3' Reverse primers 5'-3' probes 5'-3'
1 5'-TGCAAAGTACTCAGAAGAATTGTGGTA-3' 5'-TTCGCAGAAAACCAGCTATATCCT-3' 5'-FAM–CCGATTTGTATTTCACTACT- NFQ-MGB-3'
2 5’-CTGTTTCCCTTTCGACTATCTACCTT-3’ 5’-CACTGAATATCTCGAGGGAGTATGAA-3’ 5’-FAM-TCGCACATAGTCTGATTAT- MGB-3’
3 5’-TGCGATAAGGTAGATAGTCGAAAGG-3’ 5’-CCCACTTCTTAACTGTTTTAGATATCCA-3’ 5’-FAM-ACAGCCCAGAACAGTAATTAAAGCTCCCCA-BHQ1-3’
5 5’-TCATGACCCTTATGAAGTGGGC-3’ 5’-GCTCCGACTTCCATCATTGC-3’ 5’-FAM-ACGTGCTGCAAAATTTTCTACAATGGG-BHQ1-3’
6 5′-GATCCGAGACATGGTCGCTATT-3' 5'-TTCAACCTCCTTCATGGAAACAG-3' 5'-TGTTGCAGCGATTTTCCGCGGTA-3'
7 5'-TGCAAAGTACTCAGAAGAATTGTGGTA-3' 5'-TTCGCAGAAAACCAGCTATATCCT-3' 5'-FAM-CCGATTTGTATTTCACTACT-BHQ1-3'
8 5'-GCACTGAATATCTCGAGGGAGTATG-3' 5'-TTGGGAGCTTTAATTACTGTTCTGG-3' 5'-FAM-TGTTTCCCTTTCGACTATC-3'-MGB
9 5’-CTGTTTCCCTTTCGACTATCTACCTT-3’ 5’-CACTGAATATCTCGAGGGAGTATGAA-3’ 5’-FAM-TCGCACATAGTCTGATTAT- MGB-3’
10 5’-TCATGACCCTTATGAAGTGGGC-3’ 5’-GCTCCGACTTCCATCATTGC-3’ 5’-FAM-ACGTGCTGCAAAATTTTCTACAATGGG-BHQ1-3’
11 5'-GAATGCAAATCYTTACAGACAACAG-3' 5'-AAATCATGAACGAAATAACCATTGC-3' 5'-CAAAAATAACAYTSACATCAACRAGGCG-fluorescein-3' 5'-Red 640-TGCAAACCAACCAAGTGTACGACAGG-3'
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Supplemental Table 2: Questions send to each participant 
 
 
 
Username
Last name and first name
Name and address of your lab ?
Country of your lab
Country code
Did the samples arrive frozen?
If the samples arrived thawed, indicate the duration of the conservation at 4°C (days)
Sample volume received (µL)
Sample volume tested (µL)
Which PCR cycling platform do you use ?
Which qPCR detection method do you use?
How many cycles did you performed ?
What is the target gene of you PCR ?
What is the hybridization temperature (°C) used?
What is the concentration (ÎµM) of primers and probe (primers/probe) do you use?
Final volume of the PCR reaction
Did you use a rt-PCR step before amplification ?
Which Cq determination method do you use?
Did you tested an Internal control (IC)
If you performed an IC, explain which kit and which protocol
What is the reference paper of your PCR (PMID)?
If in house PCR, what buffer/enzyme kit to you use (add reference) ?
If commercial assay, indicate the exact kit name with reference and batch:
If in house assay unpublished, indicate the primers and probes used:
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Supplemental Table 3: Detailed Cq value for each assay tested in the multicentric study 
 
 
Cq=45 corresponds to a negative qPCR result 
 
  
Assay ID Center ID 1:1 (Cq1/Cq2) 1:100 (Cq1/Cq2) 1:1000 (Cq1/Cq2)
1 A 28.1/28.2 35.2/35.7 38.1/38.3
2 B 27.2/27.4 34.4/33.3 38.3/45
2 C 27.3/27.7 33.7/33.8 36.2/45
2 E 28.57/28.82 35.46/35.55 38.44/37.95
2 J 28.44/27 34.34/33.02 38.53/35.53
2 O 26.55/26.41 34.47/37.73 38.07/45
3 D 26.4/26.65 33.39/33.03 36.54/45
4 F 26.63/26.5 45/34.67 33.16/33.54
5 E 27.52/26.87 33.15/33.28 35.79/35.56
6 H 34.7/35.2 38.2/45 45/45
7 I 27.2/27.7 35/34.9 38.7/39.8
8 M 23.9/23.9 30.5/30.5 34.6/34
9 E 24.98/25.7 32.2/31.63 36.38/35.74
10 E 22.9/23.91 28.94/29.34 30.4/30.63
12 K 23.99/23.99 30.2/31.12 34.55/33.53
12 P 27.5/27.6 34.1/34.7 37/37.4
13 N 24.2/24.8 31.6/31.2 35/35.2
14 K 25.4/25.13 31.69/32.49 35.45/36.09
15 L 23.28/23.61 30.11/31.33 38.29/37.18
16 G 30.7/30.7 36.6/37.7 39.2/45
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Supplemental Table 4: Prediction model 
 
Cq Contrast Std. Err. z P  95% Conf. Interval 
1:100 vs 1:1000  -3.814 0.536 -7.11 0.0001 -4.865 -2.763 
1:1 vs 1:1000  -11.005 0.564 -19.50 0.0001 -12.111 -9.899 
1:1 vs 1:100  -7.191 0.536 -13.41 0.0001 -8.242 -6.140 
The mean effect on Cq was evaluated after ANOVA as mean difference between two levels of relative genomic load. 
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Supplemental Table 5: Detailed protocol for the 5 mtLSU qPCR assays using the same primer/probe target (Alanio et al. CMI 2011) 
 
 
Cq=45 corresponds to a negative qPCR result 
 
 
 
  
Center ID B C E J O
Sample volume tested (µL) 5 5 5 5 5
Cycler type ABI 7500 (Applied Biosystem) Roche LC480 Roche LC480 Roche LC480 ABI 7500 (Applied 
Biosystem)
qPCR method Hydrolysis probe (Taqman) Hydrolysis probe (Taqman) Hydrolysis probe (Taqman) Hydrolysis probe (Taqman) Hydrolysis probe 
(Taqman)
nb of cycles 45 45 50 50 45
Hybridization temperature (°C) 60 60 60 60 60
Primer/probe concentration (µM) 0.4/0.2 0.4/0.2 0.3/0.1 0.4/0.2 0.4/0.2
Final volume of the PCR reaction (µL) 25 20 25 20 25
Cq determination method Fit point calculation 2nd derivative calculation 2nd derivative calculation 2nd derivative calculation Fit point calculation
Internal control tested No Yes Yes No Yes
Internal control kit / Diagenode - DICU-YD-L100 Diagenode - DICU-YD-L100 / TaqMan Exogenous 
Internal Positive 
Control Reagents
Buffer/enzyme kit Applied Biosystems TaqMan Fast Universal 
PCR Master Mix
Takyon No ROX Probe 2X 
MasterMix UNG 
Eurogentec
Roche probes master mix LC480 probe master TaqMan Universal 
PCR Master Mix
1:1 (Cq1/Cq2) 27.2/27.4 27.3/27.7 28.57/28.82 28.44/27 26.55/26.41
1:100 (Cq1/Cq2) 34.4/33.3 33.7/33.8 35.46/35.55 34.34/33.02 34.47/37.73
1:1000 (Cq1/Cq2) 38.3/45 36.2/45 38.44/37.95 38.53/35.53 38.07/45
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Supplemental Table 6: Effects of the WNA/DNA procedures on the signal intensity on the Cq values of P. jirovecii detection 
 
Specimen Procedure 1 
Procedure 
2 Effects Std.Error P Better 
1:1000 RT-qPCR qPCR -3.567 1.105 0.001 first 
1:100  RT-qPCR qPCR -4.125 1.040 0.0001 first 
1:1 RT-qPCR qPCR -3.539 1.042 0.001 first 
The effects of the WNA/DNA procedures on the signal intensity (Cq) ar reported as pairwise contrasts (mean differences), at each target load. 
Significant (P < 0.05) results are included. WNA procedure was superior at all target loads, with higher qPCR signal levels. 
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Supplemental Table 7:  Effect of the target gene on the Cq values of P. jirovecii detection 
 
Target 
load Gene 1 Gene 2 Contrast Std. Err. P Better 
1:1000 mtLSU MSG -4.439 2.083 0.033 first 
 mtSSU MSG -9.023 2.397 0.0001 first 
 mtLSU TUB -7.339 2.083 0.0001 first 
 mtSSU TUB -11.923 2.397 0.0001 first 
 mtSSU mtLSU -4.585 1.298 0.0001 first 
1:100 mtSSU MSG -5.991 2.397 0.012 first 
 mtLSU TUB -7.862 2.083 0.0001 first 
 mtSSU TUB -10.441 2.397 0.0001 first 
 mtSSU mtLSU -2.579 1.298 0.047 first 
1:1 mtLSU MSG -4.314 2.083 0.038 first 
 mtSSU MSG -5.418 2.397 0.024 first 
 mtLSU TUB -8.564 2.083 0.0001 first 
 mtSSU TUB -9.668 2.397 0.0001 first 
The effects of the target genes on the signal intensity expressed as Cq are reported as pairwise contrasts (mean differences), at each target load. 
Only significant (P < 0.05) results are included. Mitochondrial Large Sub-Unit (mtLSU); mitochondrial Small Sub-Unit (mtSSU); Major Surface 
Glycoprotein (MSG); beta-tubulin (TUB). 
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Supplemental Table 8: Detailed Cq values and efficiency for each assay tested in the monocentric intra-laboratory study 
 
 
 
Cq=45 corresponds to a negative qPCR result 
 
Assay ID Target BALF1 (Cq1/Cq2) BALF2 (Cq1/Cq2) BALF3 (Cq1/Cq2) BALF4 (Cq1/Cq2) BALF5 (Cq1/Cq2) BALF6 (Cq1/Cq2) BALF7 (Cq1/Cq2) BALF8 (Cq1/Cq2) BALF9 (Cq1/Cq2) PCR Efficiency (%)
2 qPCR mtLSU 26.92/26.87 33.57/34.27 34.81/35.37 30.18/29.86 33.9/34.95 35.87/34.9 36.18/35.3 45/45 23.7/23.56 97
5 qPCR mtSSU 23.65/23.67 30.57/30.78 31.72/31.7 26.7/27.17 32.96/32.64 32.17/32.59 33.56/33.85 45/35.49 20.49/20.57 102
9 RT-qPCR mtLSU 22.73/22.72 28.93/28.89 31.17/31.36 24.52/24.59 33.27/45 32.21/32.18 34.31/33.44 34.64/34.75 19.9/19.91 96
10 RT-qPCR mtSSU 20.26/20.16 26.44/26.68 27.99/28.02 22.19/22.52 29.06/29.12 28.89/28.93 29.5/29.54 29.79/29.7 17.55/17.55 101,5
11 qPCR MSG 24.73/24.62 32.03/31.79 34.72/34.7 27.85/27.63 36.06/35.16 33.59/34.08 35.68/35.81 45/45 20.48/20.55 98
12 qPCR mtLSU 24.69/24.68 31.8/31.72 34.2/33.01 27.06/27.3 34.28/33.42 34.68/34.68 35.46/36.72 45/45 21.54/21.12 113
15 RT-qPCR mtLSU 23.04/22.84 28.79/28.76 31.26/31.11 24.59/25 33.13/33.16 32.38/31.81 34.17/33.75 34.24/34.11 20.66/19.93 105
17 qPCR mtLSU 23.95/24.03 30.16/30.47 31.26/31.14 26.89/26.9 31.03/31.4 31.59/31.61 32.03/32.19 45/34.09 21.31/21.11 111,5
18 qPCR mtLSU 24.59/24.37 31.73/32.46 33.06/33.13 27.5/27.59 34.53/34.16 34.49/34.46 35.68/35.73 45/45 21.75/21.15 94
19 qPCR mtLSU 22.27/22.29 30.3/30.47 32.04/32.14 25.86/25.83 33.57/32.91 33.07/32.67 33.95/35 35/45 19.31/19.61 96,5
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